

1 **TILTomorrow today: dynamic factors predicting changes**
2 **in intracranial pressure treatment intensity after traumatic**
3 **brain injury**

4
5 **Shubhayu Bhattacharyay^{1,2,3,*}, Florian D van Leeuwen⁴, Erta Beqiri⁵, Cecilia**
6 **Åkerlund⁶, Lindsay Wilson⁷, Ewout W Steyerberg⁴, David W Nelson⁶, Andrew I R**
7 **Maas^{8,9}, David K Menon¹, Ari Ercole^{1,10}, and the CENTER-TBI investigators and**
8 **participants[†]**

9
10 ¹Division of Anaesthesia, University of Cambridge, Cambridge, United Kingdom.

11 ²Department of Clinical Neurosciences, University of Cambridge, Cambridge, United
12 Kingdom.

13 ³Harvard Medical School, Boston, MA, USA.

14 ⁴Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden,
15 The Netherlands.

16 ⁵Brain Physics Laboratory, Division of Neurosurgery, University of Cambridge,
17 Cambridge, United Kingdom.

18 ⁶Department of Physiology and Pharmacology, Section for Perioperative Medicine and
19 Intensive Care, Karolinska Institutet, Stockholm, Sweden.

20 ⁷Division of Psychology, University of Stirling, Stirling, United Kingdom.

21 ⁸Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium.

22 ⁹Department of Translational Neuroscience, Faculty of Medicine and Health Science,
23 University of Antwerp, Antwerp, Belgium.

24 ¹⁰Cambridge Centre for Artificial Intelligence in Medicine, Cambridge, United Kingdom.

25
26 *Corresponding author: sb2406@cam.ac.uk (SB)

27 †A full list of the CENTER-TBI investigators and participants are listed after the
28 acknowledgements.

29 ABSTRACT

30
31 Practices for controlling intracranial pressure (ICP) in traumatic brain injury (TBI) patients
32 admitted to the intensive care unit (ICU) vary considerably between centres. To help
33 understand the rational basis for such variance in care, this study aims to identify the
34 patient-level predictors of changes in ICP management. We extracted all heterogeneous
35 data (2,008 pre-ICU and ICU variables) collected from a prospective cohort ($n=844$, 51
36 ICUs) of ICP-monitored TBI patients in the Collaborative European NeuroTrauma
37 Effectiveness Research in TBI (CENTER-TBI) study. We developed the TILTomorrow
38 modelling strategy, which leverages recurrent neural networks to map a token-embedded
39 time series representation of all variables (including missing values) to an ordinal,
40 dynamic prediction of the following day's five-category therapy intensity level (TIL^(Basic))
41 score. With 20 repeats of 5-fold cross-validation, we trained TILTomorrow on different
42 variable sets and applied the TimeSHAP (temporal extension of SHapley Additive
43 exPlanations) algorithm to estimate variable contributions towards predictions of next-day
44 changes in TIL^(Basic). Based on Somers' D_{xy} , the full range of variables explained 68%
45 (95% CI: 65–72%) of the ordinal variation in next-day changes in TIL^(Basic) on day one and
46 up to 51% (95% CI: 45–56%) thereafter, when changes in TIL^(Basic) became less frequent.
47 Up to 81% (95% CI: 78–85%) of this explanation could be derived from non-treatment
48 variables (i.e., markers of pathophysiology and injury severity), but the prior trajectory of
49 ICU management significantly improved prediction of future de-escalations in ICP-
50 targeted treatment. Whilst there was no significant difference in the predictive
51 discriminability (i.e., area under receiver operating characteristic curve [AUC]) between
52 next-day escalations (0.80 [95% CI: 0.77–0.84]) and de-escalations (0.79 [95% CI: 0.76–
53 0.82]) in TIL^(Basic) after day two, we found specific predictor effects to be more robust with
54 de-escalations. The most important predictors of day-to-day changes in ICP management
55 included preceding treatments, age, space-occupying lesions, ICP, metabolic
56 derangements, and neurological function. Serial protein biomarkers were also important
57 and may serve a useful role in the clinical armamentarium for assessing therapeutic
58 needs. Approximately half of the ordinal variation in day-to-day changes in TIL^(Basic) after
59 day two remained unexplained, underscoring the significant contribution of unmeasured
60 factors or clinicians' personal preferences in ICP treatment. At the same time, specific
61 dynamic markers of pathophysiology associated strongly with changes in treatment
62 intensity and, upon mechanistic investigation, may improve the timing and personalised
63 targeting of future care.

64 MAIN TEXT

65

66 Introduction

67

68 When traumatic brain injury (TBI) patients are admitted to the intensive care unit (ICU), a
69 core focus of their care is to protect and promote potential recovery in brain tissue by
70 either preventing or mitigating raised intracranial pressure (ICP).¹ To date, the
71 heterogeneous pathophysiological mechanisms that elevate ICP after TBI are not
72 sufficiently characterised for patient-tailored treatment (i.e., precision medicine).^{2,3}
73 Therefore, consensus-based guidelines^{4,5} encourage a precautionary, stepwise
74 approach⁶ to ICP management, in which therapeutic intensity – defined by the perceived
75 risk and complexity of each treatment plan – is incrementally escalated until adequate
76 ICP control is achieved. The overall intensity of a patient’s ICP management can be
77 measured on the latest Therapy Intensity Level (TIL) scale,⁷ which was developed by the
78 interagency TBI Common Data Elements (CDE) scheme⁸ and prospectively validated
79 thereafter.^{7,9}


80

81 An analysis of high-TIL treatment administration across 52 ICUs participating in the
82 Collaborative European NeuroTrauma Effectiveness Research in TBI (CENTER-TBI)
83 study^{10,11} revealed frequent deviation from the recommended stepwise approach, even
84 with ICP monitoring.¹² In fact, there was substantial between-centre variation in ICP
85 management (according to TIL) without commensurate variation in six-month functional
86 outcome on the Glasgow Outcome Scale – Extended (GOSE).^{13,14} Baseline injury
87 severity factors, imaging results, and ICP explained only 8.9% of the pseudo-variance in
88 dichotomised high-TIL treatment use.¹² These results raised the questions about whether
89 contemporary ICP management is performed in a systematic, rational manner in practice
90 and whether some patients are being exposed to unnecessary risks with high-TIL
91 therapies. Answering these questions requires consideration of a patient’s full, time-
92 varying clinical course as well as a more detailed representation of different levels of the
93 TIL scale.

94

95 As a first step towards answering the questions above, we aim to identify factors
96 associated with ICP-targeted treatment decisions on an individual patient level.
97 Expanding upon our previous work,^{13,15} we propose a modelling strategy (TILTomorrow)
98 which dynamically predicts next-day TIL^(Basic) – the five-category version of TIL – from all
99 pre-ICU and ICU data prospectively recorded for the CENTER-TBI study (Fig. 1). Our
100 primary objective in developing TILTomorrow was to determine how well a patient’s full
101 clinical course can predict upcoming changes in ICP treatment intensity. Our second
102 objective was to estimate the differential contribution of pathophysiological severity, the
103 preceding trajectory of treatment, and unmeasured factors (e.g., personal treatment
104 preferences) towards explanation of next-day changes made to TIL^(Basic). Our third
105 objective was to mine the full dataset for dynamic predictors of day-to-day changes in
106 TIL^(Basic).

107



109 **Fig. 1. TILTomorrow prediction task and modelling strategy.** All shaded regions surrounding curves
 110 are 95% confidence intervals derived using bias-corrected bootstrapping (1,000 resamples) to represent
 111 the variation across the patient population and across the 20 repeated five-fold cross-validation partitions.
 112 (a) Illustration of the TILTomorrow dynamic prediction task on a sample patient's timeline of ICU stay. The
 113 objective of the task is to predict the next-day $TIL^{(Basic)}$ score at each calendar day of a patient's ICU stay.
 114 The prediction is dynamic, updated for each calendar day, and must account for temporal variation of
 115 variables across all preceding days using a time-series model (f_t). (b) Illustration of the TILTomorrow
 116 modelling strategy on a sample patient's timeline of ICU stay. Each patient's ICU stay is first discretised

117 into non-overlapping time windows, one for each calendar day. From each time window, values for up to
118 979 dynamic variables were combined with values for up to 1,029 static variables to form the variable set.
119 The variable values were converted to tokens by discretising numerical values into 20-quantile bins from
120 the training set and removing special formatting from text-based entries. Through an embedding layer, a
121 vector was learned for each token encountered in the training set, and tokens were replaced with these
122 vectors. A positive relevance weight, also learned for each token, was used to weight-average the vectors
123 of each calendar day into a single, low-dimensional vector. The sequence of low-dimensional vectors
124 representing a patient's ICU stay were fed into a gated recurrent neural network (RNN). The RNN outputs
125 were then decoded at each time window into an ordinal prognosis of next-day TIL^(Basic) score. The highest-
126 intensity treatments associated with each threshold of TIL^(Basic) are decoded in Table 1. (c) Probability
127 calibration slope, at each threshold of next-day TIL^(Basic), for models trained on the full variable set. The
128 ideal calibration slope of one is marked with a horizontal orange line. (d) Ordinal probability calibration
129 curves at four different days after ICU admission. The diagonal dashed line represents the line of perfect
130 calibration. The values in each panel correspond to the maximum absolute error (95% confidence interval)
131 between the curve and the perfect calibration line. Abbreviations: CT=computerised tomography,
132 ER=emergency room, f_t =time-series model, GRU=gated recurrent unit, Hx=history, ICP=intracranial
133 pressure, ICU=intensive care unit, LSTM=long short-term memory, N/A=not available, NF-L=neurofilament
134 light chain, SES=socioeconomic status, TIL=Therapy Intensity Level, TIL^(Basic)=condensed, five-category
135 TIL scale as defined in Table 1, VE=vascular endothelial.

136

137 **Methods**

138

139 ***Study design and participants***

140

141 CENTER-TBI is a longitudinal, observational cohort study (NCT02210221) involving 65
142 medical centres across 18 European countries and Israel.^{10,11} Patients were recruited
143 between 19 December 2014 and 17 December 2017 if they met the following criteria: (1)
144 presentation within 24 hours of a TBI, (2) clinical indication for a computerised
145 tomography (CT) scan, and (3) no severe pre-existing neurological disorder. In
146 accordance with relevant laws of the European Union and the local country, ethical
147 approval was obtained for each site, and written informed consent by the patient or legal
148 representative was documented electronically. The list of sites, ethical committees,
149 approval numbers, and approval dates can be found online: [https://www.center-](https://www.center-tbi.eu/project/ethical-approval)
150 [tbi.eu/project/ethical-approval](https://www.center-tbi.eu/project/ethical-approval). The project objectives and design of CENTER-TBI have
151 been described in detail previously.^{10,11}

152

153 In this work, we apply the following additional inclusion criteria: (1) primary admission to
154 the ICU, (2) at least 16 years old at ICU admission, (3) at least 24 hours of ICU stay, (4)
155 invasive ICP monitoring, (5) no decision to withdraw life-sustaining therapies (WLST) on
156 the first day of ICU stay, and (6) availability of daily TIL assessments from at least two
157 consecutive days.

158

159 ***Therapy intensity level (TIL)***

160

161 The endpoint for the TILTomorrow dynamic prediction task (Fig. 1a) is the next-day
162 TIL^(Basic) score. The TIL^(Basic) scale was developed through an international expert panel
163 to serve as a five-category summary of the full, 38-point TIL score.⁸ TIL^(Basic) categorises
164 overall ICP treatment intensity over a given period of time by selecting the highest

165 classification of ICP control amongst all treatments administered in that period of time, as
166 defined in Table 1. By convention, a decompressive craniectomy for refractory intracranial
167 hypertension is scored with $TIL^{(Basic)}=4$ (i.e., extreme ICP control) for every subsequent
168 timepoint. As described later, we account for this effect in our analysis by: (1) referencing
169 TILTomorrow performance against simply carrying forward the last-available $TIL^{(Basic)}$
170 score and against models trained without treatment (e.g. incidence of decompressive
171 craniectomy) or clinician-impression (e.g., reason for decompressive craniectomy)
172 variables, and (2) focusing only on variables that occur at least a day before a change in
173 $TIL^{(Basic)}$. Since daily use of $TIL^{(Basic)}$ was prospectively validated,⁷ we calculate the
174 $TIL^{(Basic)}$ score over each available calendar day of a patient's ICU stay. For the CENTER-
175 TBI study, information pertaining to the $TIL^{(Basic)}$ treatments (Table 1) was recorded on
176 days 1–7, 10, 14, 21, and 28 of ICU stay. $TIL^{(Basic)}$ score calculations were excluded on
177 or after the day of any WLST decision. As an overall summary metric, we also calculated
178 $TIL^{(Basic)}_{median}$ – the median of the daily $TIL^{(Basic)}$ scores over days 1–7 of ICU stay.

179
180 We elected not to use the full TIL score as the model endpoint since it is a point-sum
181 (rather than a truly categorical) score, and the same value changes in TIL can be the
182 result of changing treatments across different intensities. For instance, administering
183 head elevation, low-volume cerebrospinal fluid drainage, and low-dose mannitol is
184 numerically 'equivalent' to performing a last-resort decompressive craniectomy.⁷ On the
185 contrary, changes in $TIL^{(Basic)}$ correspond to transitions across specific, interpretable
186 bands of treatment intensity (Table 1).

187

Table 1. TIL^(Basic) scale treatments and representation in study population

Classification of ICP control	ICP-targeting treatment	Study representation (count)	
		Patients (844 total)	Centres (51 total)
(4) Extreme	High-dose propofol or barbiturates (metabolic suppression)	490 (58%)	50 (98%)
	Intensive hyperventilation ($P_aCO_2 < 30$ mmHg)	315 (37%)	46 (90%)
	Therapeutic hypothermia ($< 35^\circ C$)	61 (7.2%)	24 (47%)
	Intracranial operation for progressive mass lesion (not scheduled at admission)	93 (11%)	31 (61%)
	Intracranial operation for progressive mass lesion (not scheduled at admission)	149 (18%)	40 (78%)
	Decompressive craniectomy for refractory intracranial hypertension*	76 (9.0%)	29 (57%)
(3) Moderate	High-volume CSF drainage (≥ 120 mL/24h)	344 (41%)	47 (92%)
	Moderate hyperventilation ($30 \leq P_aCO_2 < 35$ mmHg)	212 (25%)	41 (80%)
	Higher-dose mannitol (> 2 g/kg/24h)	235 (28%)	41 (80%)
	Higher-dose hypertonic saline (> 0.3 g/kg/24h)	45 (5.3%)	22 (43%)
	Higher-dose hypertonic saline (> 0.3 g/kg/24h)	128 (15%)	33 (65%)
	Cooling for ICP control ($\geq 35^\circ C$)	146 (17%)	32 (63%)
(2) Mild	Higher-dose sedation for ICP control (not aiming for burst suppression)	645 (76%)	50 (98%)
	Low-volume CSF drainage (< 120 mL/24h)	561 (66%)	48 (94%)
	Fluid loading for CPP management	221 (26%)	41 (80%)
	Vasopressor therapy for CPP management	511 (61%)	48 (94%)
	Mild hyperventilation ($35 \leq P_aCO_2 < 40$ mmHg)	720 (85%)	50 (98%)
	Lower-dose mannitol (≤ 2 g/kg/24h)	509 (60%)	48 (94%)
	Lower-dose hypertonic saline (≤ 0.3 g/kg/24h)	197 (23%)	41 (80%)
	Lower-dose hypertonic saline (≤ 0.3 g/kg/24h)	303 (36%)	41 (80%)
(1) Basic	Head elevation for ICP control	406 (48%)	45 (88%)
	Nursed flat (180°) for CPP management	765 (91%)	50 (98%)
	Lower-dose sedation for mechanical ventilation	123 (15%)	31 (61%)
	Lower-dose sedation for mechanical ventilation	753 (89%)	50 (98%)
(0) None		338 (40%)	48 (94%)

189 The TIL^(Basic) scale was developed by Maas *et al.*⁸ and prospectively validated by Bhattacharyay *et al.*⁷ The TIL^(Basic) score is determined by selecting
190 the highest classification of ICP control (first column) among all the ICP-targeting treatments (second column) administered to a patient over a
191 calendar day. The study representation of each TIL^(Basic) category and each ICP-targeting treatment is the count (and percentage) of patients who
192 received the corresponding (category of) treatment in the study population as well as the count (and percentage) of centres who administered the
193 corresponding (category of) treatment in the study population.

194 *If a decompressive craniectomy is performed as a last resort for refractory intracranial hypertension, its score is included in the day of the operation
195 and in every subsequent day of ICU stay.

196 Abbreviations: CPP=cerebral perfusion pressure, CSF=cerebrospinal fluid, ICP=intracranial pressure, ICU=intensive care unit, P_aCO_2 =partial
197 pressure of carbon dioxide in arterial blood, TIL=Therapy Intensity Level scale, TIL^(Basic)=condensed TIL scale.

198 **Model variables**

199
 200 We extracted all variables collected before and during ICU stays for the CENTER-TBI
 201 core study¹¹ (v3.0, ICU stratum) using Opal database software.¹⁶ These variables were
 202 sourced from medical records and online test results and include structured (i.e.,
 203 numerical, binary, or categorical), unstructured (i.e., free text), and missing values. We
 204 manually excluded variables which explicitly indicate death or WLST (Supplementary
 205 Table S1), and, if a decision to WLST was made during any point of a patient's ICU stay,
 206 we only extracted model variables before the timestamp of WLST decision. We also
 207 added features extracted from automatically segmented and expert-corrected high-
 208 resolution CT and magnetic resonance (MR) images. These features correspond to the
 209 type, location, and volume of space-occupying lesions, and the process of their extraction
 210 has been described in detail previously.^{17,18} In total, we included 2,008 variables: 1,029
 211 static (i.e., fixed at ICU admission) variables and 979 dynamic variables (i.e., collected
 212 during ICU stay) with varying sampling frequencies. We qualitatively organised the
 213 variables into the nine categories listed in Table 2 and further indicated whether variables
 214 represented an intervention during ICU admission (e.g., administration and type of
 215 glucose management) or a physician-based impression (e.g., reason for not pursuing
 216 intracranial surgery following CT scan, Supplementary Table S2). Descriptions for each
 217 of the variables can be viewed online at the CENTER-TBI data dictionary:
 218 <https://www.center-tbi.eu/data/dictionary>.

219
 220 **Table 2. Variable count per category and subtype**

Category	Example variable	Count by subtypes			
		All	Static	Dynamic	Interventions and physician impressions
Demographics and socioeconomic status	Years of formal education	22	22	0	0
Medical and behavioural history	Number of prior TBIs or concussions	186	186	0	0
Injury characteristics and severity	Airbag deployed during accident	84	84	0	0
Emergency care and ICU admission	Blood transfusion in ER	234	234	0	14
Brain imaging reports	Cortical sulcal effacement	939	425	514	19
Laboratory measurements	Serum level of UCH-L1	228	75	153	6
ICU medications and management	Vasopressor dose	141	3	138	127
ICU vitals and assessments	Types of seizures in past day	125	0	125	0
Surgery and neuromonitoring	Ventriculostomy for CSF drainage	49	0	49	39
Total		2008	1029	979	205

221 Data represent the number of subtype (*column*) variables per category (*row*).
 222 Abbreviations: CSF=cerebrospinal fluid, ER=emergency room, ICU=intensive care unit, SBP=systolic blood
 223 pressure, TBI=traumatic brain injury, UCH-L1=ubiquitin carboxy-terminal hydrolase L1.

224 225 **TIL Tomorrow modelling strategy**

226

227 Whilst strong predictors of functional outcome after TBI are known, this is not the case
228 for TIL. Thus, the TILTomorrow modelling strategy was designed to include *all* static and
229 dynamic variables from CENTER-TBI to produce an evolving prediction of the next
230 calendar day's TIL^(Basic) over each patient's ICU stay. The large number of variables
231 precludes building such a model by manual feature extraction, motivating our flexible
232 tokenisation-and-embedding approach with no constraints on the number or type of
233 variables per patient. We trained models, through supervised machine learning, with three
234 main components based on our prior studies^{13,15,19}: (1) a token-embedding encoder, (2)
235 a gated recurrent neural network (RNN), and (3) an ordinal endpoint output layer. We
236 created 100 partitions of our patient population for repeated *k*-fold cross-validation (20
237 repeats, 5 folds) with 15% of each training set randomly set aside as an internal validation
238 set.

239
240 ICU stays were partitioned into non-overlapping time windows, one per calendar day (Fig.
241 1a). Static variables were carried forward across all windows (Fig. 1b). All variables were
242 tokenised through one of the following methods: (1) for categorical variables, appending
243 the value to the variable name, (2) for numerical variables, learning the training set
244 distribution and discretising into 20 quantile bins, (3) for text-based entries, removing all
245 special characters, spaces, and capitalisation from the text and appending to the variable
246 name, and (4) for missing values, creating a separate token to designate missingness
247 (Fig. 1b). We selected 20 quantile bins for discretisation based on optimal performance
248 in our previous work.^{13,19} By labelling missing values with separate tokens instead of
249 imputing them, the models could learn potentially significant patterns of missingness and
250 integrate a diverse range of missing data without needing to validate the assumptions of
251 imputation methods on each variable.²⁰ During training, the models learned a low-
252 dimensional vector (of either 128, 256, 512, or 1,024 units) and a 'relevance' weight for
253 each token in the training set. Therefore, models would take the unique tokens from each
254 time window of a patient, replace them with the corresponding vectors, and average the
255 vectors – each weighted by its corresponding relevance score – into a single vector per
256 time window (Fig. 1b).

257
258 Each patient's sequence of low-dimensional vectors then fed into a gated RNN – either a
259 long short-term memory (LSTM) network or a gated recurrent unit (GRU) – to output
260 another vector per time window. In this manner, the models learned temporal patterns of
261 variable interactions from training set ICU records and updated outputs with each new
262 time window of data. Finally, each RNN output vector was decoded with a multinomial
263 (i.e., softmax) output layer to return a probability at each threshold of next-day TIL^(Basic)
264 over time (Fig. 1b). From these outputs, we also calculated the probabilities of TIL^(Basic)
265 decreasing, staying the same, or increasing tomorrow in relation to the last available
266 TIL^(Basic) score (Supplementary Methods S1). Please note that both threshold-level
267 probability estimates and estimated probabilities of next-day changes in TIL^(Basic) are
268 derived from the outputs of the same model, as described in Supplementary Methods S1.

269
270 The combinations of hyperparameters – in addition to those already mentioned
271 (embedding vector dimension and RNN type) – and the process of their optimisation in
272 the internal validation sets are reported in Supplementary Methods S2–S3.

273

274 **Model and information evaluation**

275

276 All metrics, curves, and associated confidence intervals (CIs) were calculated on the
277 testing sets using the repeated Bootstrap Bias Corrected Cross-Validation (BBC-CV)
278 method,²¹ as described in Supplementary Methods S2. We calculated metrics and CIs at
279 each day directly preceding a day of TIL assessment in our study population (i.e., days
280 1–6, 9, 13, 20, and 27).

281

282 The reliability of model-generated prediction trajectories was assessed through the
283 calibration of output probabilities at each threshold of next-day TIL^(Basic). Using the logistic
284 recalibration framework,²² we first measured calibration slope. Calibration slope
285 less(/greater) than one indicates overfitting(/underfitting).²² Additionally, we examined
286 smoothed probability calibration curves to detect miscalibrations that might have been
287 overlooked by the logistic recalibration framework.²²

288

289 To evaluate prediction discrimination performance, we calculated the area under the
290 receiver operating characteristic curve (AUC) at each threshold of next-day TIL^(Basic).
291 These AUCs are interpreted as the probability of the model correctly discriminating a
292 patient whose next-day TIL^(Basic) is above a given threshold from one with next-day
293 TIL^(Basic) below. Moreover, we calculated the AUC for prediction of next-day escalation
294 and de-escalation in TIL^(Basic). In this case, the AUC represents the probability of the
295 model correctly discriminating a patient who experienced a day-to-day (de-)escalation in
296 TIL^(Basic) from one who did not.

297

298 We also assessed the information quality achieved by the combination of our modelling
299 strategy and the CENTER-TBI variables in predicting next-day changes in TIL^(Basic) by
300 calculating Somers' D_{xy} .²³ In our context, Somers' D_{xy} is interpreted as the proportion of
301 ordinal variation in day-to-day changes of TIL^(Basic) that is explained by the variation in
302 model output.²⁴ The calculation of Somers' D_{xy} is detailed in Supplementary Methods S4.

303

304 We compared the performance of the TILTomorrow modelling strategy trained on the
305 following factors to test their differential contribution to prediction: (1) the full variable set
306 [2,008 variables], (2) all variables excluding physician-based impressions and treatments
307 (e.g., all variables related to TIL) [1,803 variables], and (3) only static variables repeated
308 in each time window [1,029 variables]. Our rationale for these ablated variable sets was
309 to estimate the extent to which: (1) predictable trajectories of care – independent of other
310 measured factors – influence treatment planning and (2) ICP treatments are responding
311 to recorded events that occur over a patient's ICU stay. To serve as our reference for
312 model comparison, we also calculated the performance achieved by simply carrying over
313 the last available TIL^(Basic) for prediction of next-day TIL^(Basic). This reference performance
314 accounts not only for the proportion of the population that did not change in TIL^(Basic) on a
315 given day but also for the change in the assessment population caused by patient
316 discharge over time.

317

318 **Contributors to transitions in TIL**

319
320 We applied the TimeSHAP algorithm²⁵ on testing set predictions to find specific variables
321 associated with next-day changes in TIL^(Basic). TimeSHAP is a temporal extension of the
322 kernel-weighted SHapley Additive exPlanations (KernelSHAP) algorithm,²⁶ which
323 estimates the relative contribution (i.e., Shapley value²⁷) of each model input to a specific
324 patient's model output. In our case, this was done by masking sampled combinations of
325 tokens (i.e., coalitions) leading up to a patient's next-day change in TIL^(Basic) and
326 calculating the difference in trained model output for each combination. A kernel-weighted
327 linear regression model was then fit between binary coalition masks and resulting model
328 outputs to estimate the Shapley value for each model input. TimeSHAP extends
329 KernelSHAP by considering each unique combination of tokens and time windows as its
330 own feature. Crucially, TimeSHAP made this computationally tractable for our application,
331 in which models contain many possible tokens, by grouping low-contributing time
332 windows in the distant past together as a single feature (i.e., temporal coalition pruning).
333 TimeSHAP, KernelSHAP, and Shapley values are described in greater, mathematical
334 detail in Supplementary Methods S5.

335
336 We estimated token-level Shapley values with the TimeSHAP algorithm at both one day
337 and two days before an upcoming change in TIL^(Basic). Our chosen model output for
338 TimeSHAP was the expected next-day TIL^(Basic) score, as defined in Supplementary
339 Methods S5. We then calculated the difference between the estimated Shapley values of
340 the two consecutive days for each token to derive its Δ TimeSHAP value. If a token did
341 not exist in the window of either of the two days, then its Shapley value for that day was
342 zero. Therefore, Δ TimeSHAP values were interpreted as the contributions of variable
343 tokens towards the difference in model prediction of next-day TIL^(Basic) over the two days
344 directly preceding the change in TIL^(Basic), given the patient's full set of tokens. If a variable
345 had a positive (or negative) Δ TimeSHAP value, it was associated with an increased
346 likelihood of escalation (or de-escalation) in next-day treatment intensity. Moreover, since
347 the calculation of Δ TimeSHAP values required two days of information before the change
348 in TIL^(Basic), we only calculated the variable contributions to day-to-day changes in TIL^(Basic)
349 that occurred after day two of ICU stay.

350 351 **Results**

352 353 **Study population**

354
355 Of the 4,509 patients available for analysis in the CENTER-TBI core study, 844 patients
356 from 51 ICUs met the inclusion criteria of this work (Supplementary Fig. S1). The median
357 ICU stay duration of our population was 14 days (Q_1 – Q_3 : 8.4–23 days) and 86% ($n=722$)
358 stayed through at least seven calendar days. Since the regularity of TIL^(Basic) assessments
359 decreased substantially after 14 days, and since less than half of the population remained
360 in the ICU for 21 days (Supplementary Fig. S2), we focused our analysis on the first 14
361 days of ICU stay. Summary characteristics of the overall population as well as those
362 stratified by whether patients had a day-to-day change in TIL^(Basic) over their first week in

363 the ICU are detailed in Table 3. On average, patients who did not experience a change
 364 in TIL^(Basic) over their first week were significantly younger, had higher baseline ICP
 365 values, and resulted in poorer functional recovery at six months post-injury (Table 3).
 366 However, their mean ICU stay duration was not significantly different.

367
 368 **Table 3. Summary characteristics of the study population stratified by day-to-day changes in**
 369 **TIL^(Basic)**

Summary characteristic	Overall (<i>n</i> =844, 51 centres)	Day-to-day change in TIL ^(Basic) during first week in ICU		<i>p</i> -value [‡]
		Yes (<i>n</i> =677, 50 centres)	No (<i>n</i> =167, 40 centres)	
Age [years]	47 (29–61)	48 (30–62)	41 (27–58)	0.047
Sex: Female	212 (25%)	165 (24%)	47 (28%)	0.36
Baseline Glasgow Coma Scale (<i>n</i> *=795)				0.67
3–8	540 (68%)	426 (67%)	114 (71%)	
9–12	138 (17%)	112 (18%)	26 (16%)	
13–15	117 (15%)	96 (15%)	21 (13%)	
Baseline CT lesions (<i>n</i> *=730)				
Epidural haematoma	165 (23%)	136 (23%)	29 (19%)	0.36
Intracerebral haemorrhage	594 (81%)	480 (83%)	114 (77%)	0.11
Subdural haematoma	465 (64%)	368 (63%)	97 (65%)	0.76
Traumatic subarachnoid haemorrhage	633 (87%)	502 (86%)	131 (88%)	0.73
First-day mean ICP [mmHg] (<i>n</i> *=811)	11 (7.0–15)	10. (6.8–14)	12 (8.2–17)	<0.001
TIL ^(Basic) _{median}	2 (2–4)	2 (2–3)	4 (2–4)	<0.001
Refractory intracranial hypertension (<i>n</i> *=836)	143 (17%)	85 (13%)	58 (35%)	<0.001
ICU stay duration [days]	14 (8.4–23)	14 (8.1–23)	14 (8.8–23)	0.90
Six-month GOSE (<i>n</i> *=738)				0.018
(1) Death	181 (25%)	139 (23%)	42 (29%)	
(2 or 3) Vegetative/lower SD	181 (25%)	154 (26%)	27 (18%)	
(4) Upper SD	70 (9.5%)	48 (8.1%)	22 (15%)	
(5) Lower MD	122 (17%)	96 (16%)	26 (18%)	
(6) Upper MD	73 (10%)	65 (11%)	8 (5.5%)	
(7) Lower GR	55 (7.5%)	42 (7.1%)	13 (8.9%)	
(8) Upper GR	56 (7.6%)	48 (8.1%)	8 (5.5%)	
Baseline prognosis [†] [%] (<i>n</i> *=749)				
Pr(GOSE>1)	85 (64–94)	85 (66–95)	83 (56–93)	0.010
Pr(GOSE>3)	54 (31–75)	54 (33–76)	52 (24–71)	0.019
Pr(GOSE>4)	40. (22–59)	41 (24–60.)	38 (16–54)	0.010
Pr(GOSE>5)	22 (11–36)	22 (12–38)	19 (8.9–30.)	0.0022
Pr(GOSE>6)	13 (6.7–21)	13 (7.1–22)	11 (5.2–17)	0.0034
Pr(GOSE>7)	5.2 (2.5–9.5)	5.4 (2.7–9.9)	4.2 (2.2–8.6)	0.0071

370 Data are median (Q₁–Q₃) for numerical characteristics and *n* (% of column group) for categorical
 371 characteristics unless otherwise indicated. Units or numerical definitions of characteristics are provided in
 372 square brackets.

373 *Limited sample size of non-missing values for characteristic.

374 †Ordinal functional outcome prognostic scores were calculated through tokenised embedding of all clinical
 375 information in the first 24 hours of ICU stay, as described previously.¹⁵


376 ‡*p*-values, comparing patients who experienced a day-to-day change in TIL^(Basic) in the first week of ICU
 377 stay to those who did not, are derived from Welch's *t*-test for numeric variables and χ^2 contingency table
 378 test for categorical variables.

379 Abbreviations: CT=Computerised tomography, GOSE=Glasgow Outcome Scale–Extended, GR=good
380 recovery, ICP=intracranial pressure, ICU=intensive care unit, MD=moderate disability,
381 $\text{Pr}(\text{GOSE}>\bullet)$ ="probability of GOSE greater than \bullet at six months post-injury" as previously calculated from
382 the first 24 hours of admission,²⁷ SD=severe disability, TIL=Therapy Intensity Level scale,
383 $\text{TIL}^{(\text{Basic})}$ =condensed TIL scale as measured in Table 1 for each calendar day, $\text{TIL}^{(\text{Basic})}_{\text{median}}$ =median $\text{TIL}^{(\text{Basic})}$
384 over first week of ICU stay.

385
386 The representation of each ICP-targeting treatment and $\text{TIL}^{(\text{Basic})}$ score in our study is
387 listed in Table 1. The least-represented treatment (higher-dose mannitol) was
388 administered to 45 patients (5.3%) across 22 ICUs, whereas the least-represented
389 $\text{TIL}^{(\text{Basic})}$ score ($\text{TIL}^{(\text{Basic})}=1$) applied to 344 patients (41%) across 47 ICUs. A
390 decompressive craniectomy for refractory intracranial hypertension was performed in 76
391 patients (9.0%) across 29 ICUs, and the median timepoint for such an operation was day
392 three (Q_1 – Q_3 : two–five) of ICU stay.

393
394 The distribution of $\text{TIL}^{(\text{Basic})}$ values at each day of TIL assessment and the transitions of
395 $\text{TIL}^{(\text{Basic})}$ scores between days of assessment are visualised in Fig. 2a. No more than 2.4%
396 of the population's $\text{TIL}^{(\text{Basic})}$ scores were missing at any given assessment day, and the
397 proportion of patients receiving basic-to-no ICP-targeting treatment (i.e., $\text{TIL}^{(\text{Basic})}\leq 1$)
398 increased over time (Supplementary Fig. S2). The distribution of day-to-day changes in
399 $\text{TIL}^{(\text{Basic})}$ (Fig. 2b) demonstrates that there was considerably more change in $\text{TIL}^{(\text{Basic})}$ from
400 day one to day two than there was in any other pair of consecutive days. On the rest of
401 the days in the first week, 69–75% of the population did not experience a change in
402 $\text{TIL}^{(\text{Basic})}$ from one day to the next (Fig. 2b). The distribution of next-day $\text{TIL}^{(\text{Basic})}$ given the
403 current day's $\text{TIL}^{(\text{Basic})}$ (Supplementary Fig. S3) show that at least 79% of day-to-day
404 therapeutic transitions happen within one $\text{TIL}^{(\text{Basic})}$ category, except for escalations from
405 $\text{TIL}^{(\text{Basic})}=0$ and de-escalations from $\text{TIL}^{(\text{Basic})}=4$ from day one to two. When a change in
406 $\text{TIL}^{(\text{Basic})}$ did occur, the distributions of $\text{TIL}^{(\text{Basic})}$ before and after the change
407 (Supplementary Fig. S4) reflect a gradual trend towards de-escalation at later days of ICU
408 stay as expected.

409



411 **Fig. 2. Distributions of TIL^(Basic) and its day-to-day changes in the study population.** (a) Alluvial
 412 diagram of the evolution of the TIL^(Basic) distribution in the study population over the assessed days of ICU
 413 stay. Percentages which round to 2% or lower are not shown. (b) Distributions of day-to-day changes in
 414 TIL^(Basic). The numbers above each bar represent the number of study patients remaining in the ICU after
 415 the corresponding day-to-day step. Percentages which round to 2% or lower are not shown. Abbreviations:
 416 ICU=intensive care unit, TIL=Therapy Intensity Level, TIL^(Basic)=condensed, five-category TIL scale as
 417 defined in Table 1, WLST=withdrawal of life-sustaining therapies.

418

419 **Reliability and performance of TILTomorrow**


420

421 With both calibration slopes (Fig. 1c) and smoothed calibration curves (Fig. 1d) across
 422 the thresholds of next-day TIL^(Basic), we observed that the TILTomorrow modelling strategy
 423 achieved sufficient testing set calibration for analysis from day two of ICU stay onwards.
 424 The 95% CI of the calibration slope pertaining to prediction of next-day TIL^(Basic) > 0 was
 425 wider than that of other thresholds but still centred around a well-calibrated slope of one.
 426

427

428 In the first week of ICU stay, TILTomorrow correctly discriminated patients at each
 429 threshold of next-day TIL^(Basic) between 79% (95% CI: 77–82%) and 95% (95% CI: 93–
 430 96%) of the time (Fig. 3a). However, this apparently strong predictive power was in fact
 431 largely because TIL^(Basic) tended not to change greatly (i.e., the “inertia” of TIL) across
 432 day-to-day steps (Fig. 2b), especially at higher thresholds of next-day TIL^(Basic) (violet lines
 433 in Fig. 3a). After removing all treatments and physician-based impressions from the model
 434 variable set (including all variables related to TIL), the first-week AUCs dropped to
 435 between 0.65 (95% CI: 0.62–0.68) and 0.86 (95% CI: 0.82–0.89) with significantly lower
 436 performance at higher thresholds of next-day TIL^(Basic) (Fig. 3a). Models trained with only
 437 static variables achieved only marginally better discrimination than an uninformative
 predictor (best AUC: 0.60 [95% CI: 0.56–0.63], Fig. 3a).

438



440 **Fig. 3. Differential performance in discriminating and explaining next-day TIL^(Basic).** All shaded regions
 441 surrounding curves and error bars are 95% confidence intervals derived using bias-corrected bootstrapping
 442 (1,000 resamples) to represent the variation across 20 repeated five-fold cross-validation partitions. (a)
 443 Discrimination performance in prediction of next-day TIL^(Basic) – measured by AUC at each threshold of
 444 TIL^(Basic) – by models trained on different variable sets. The violet line represents the performance achieved
 445 by simply carrying the last available TIL^(Basic) forward to account for the effect of day-to-day stasis in TIL^(Basic)
 446 on prediction. The horizontal dashed line (AUC=0.5) represents the performance of uninformative
 447 prediction. (b) Discrimination performance in prediction of next-day de-escalation or escalation in TIL^(Basic)
 448 – measured by AUC – by models trained on different variable sets. The horizontal dashed line (AUC=0.5)
 449 represents the performance of uninformative prediction. (c) Explanation of ordinal variation in next-day
 450 changes in TIL^(Basic) – measured by Somers' D_{xy} – by models trained on different variable sets.
 451 Abbreviations: AUC=area under the receiver operating characteristic (ROC) curve, ICU=intensive care unit,
 452 TIL=Therapy Intensity Level, TIL^(Basic)=condensed, five-category TIL scale as defined in Table 1.

453
 454 To completely account for the inertia of TIL^(Basic) across day-to-day steps, we calculated
 455 discrimination performance in the prediction of changes in next-day TIL^(Basic) (Fig. 3b).
 456 Prediction performance was highest on day one across all variable sets, with the full-
 457 variable model correctly discriminating next-day de-escalations 90% (95% CI: 88–91%)
 458 of the time and next-day escalations 85% (95% CI: 83–87%) of the time. Within each
 459 variable set, change-in-TIL^(Basic) prediction performance did not change significantly from
 460 day two onwards, except for the prediction of next-day escalation from static variables.
 461 Treatment and physician-based impression variables significantly improved performance
 462 in prediction of next-day de-escalations in TIL^(Basic) but not in prediction of next-day
 463 escalations in TIL^(Basic) (Fig. 3b). Moreover, static variables achieved greater

464 discrimination in the prediction of TIL^(Basic) escalations than in the prediction of TIL^(Basic)
465 de-escalations from days two to four of ICU stay.
466

467 ***Differential explanation of next-day changes in TIL***


468
469 The full set of 2,008 variables explained 68% (95% CI: 65–72%) of the ordinal variation
470 in next-day changes in TIL^(Basic) on day one and up to 51% (95% CI: 45–56%) through the
471 rest of the first week (Fig. 3c). For the same endpoint, the 1,803 variables which exclude
472 treatments and physician-based impressions explained 60% (95% CI: 57–64%) of the
473 ordinal variation on day one and up to 35% (95% CI: 30–41%) thereafter (Fig. 3c). From
474 Fig. 3b, we found that the explanation added from the prior trajectory of ICU management
475 related more to informative patterns of treatment de-escalation than to those of
476 escalation. At the same time, most of the explanation achieved by the full variable model
477 could also be achieved without explicit information about the patient's treatments. The
478 1,029 static variables explained 54% (95% CI: 50–57%) of the ordinal variation in next-
479 day changes in TIL^(Basic) on day one and decreased in explanation significantly from days
480 two (28% [95% CI: 23–33%]) to six (13% [95% CI: 7–19%]) (Fig. 3c). In other words, the
481 explanatory impact of dynamic variables increased over time in the ICU. Most of the
482 explanatory information in static variables contributed towards prediction of treatment
483 escalations earlier in patients' ICU stays (Fig. 3b).
484

485 ***Variables associated with next-day changes in TIL***

486
487 During the days of consecutive TIL assessment that were eligible for Δ TimeSHAP
488 calculation (days 2–7), 575 patients (68% of population) experienced a total of 1,004 day-
489 to-day changes in TIL^(Basic). The associative contributions of highest-impact variables
490 towards prediction of these changes – both for models trained on all variables and for
491 those trained without treatment variables – are visualised in Fig. 4. The number of points
492 for each variable in Fig. 4 equals the number of times each variable was represented
493 across the 1,004 changes in TIL^(Basic). Moreover, we annotated several specific values of
494 categorical variables in Fig. 4 because of their visually consistent association with next-
495 day TIL^(Basic) de-escalation (i.e., negative Δ TimeSHAP) or TIL^(Basic) escalation (i.e.,
496 positive Δ TimeSHAP). Across the leading predictors of next-day changes in TIL^(Basic) (Fig.
497 4), we found the following categories of variables:

- 498 • the preceding trajectory of ICU management (e.g., extubation, prior trajectory of
- 499 TIL, ending nasogastric feeding),
- 500 • age at admission,
- 501 • bleeding risk factors (e.g., history of taking anticoagulants, baseline platelet count),
- 502 • brain imaging results (e.g., traumatic subarachnoid haemorrhage, subdural
- 503 haematoma, intraparenchymal haemorrhage),
- 504 • haemodynamics and intracranial hypertension (e.g., ICP, blood pressure,
- 505 respiratory efficiency),
- 506 • markers of systemic inflammation (e.g., ventilator-associated pneumonia [which
- 507 may also reflect long ventilation time], eosinophils),
- 508 • metabolic derangements (e.g., sodium, calcium, alanine aminotransferase),

- neurological function (e.g., Glasgow Coma Scale [GCS] eye and motor scores),
- protein biomarkers (e.g., neurofilament-light chain, total tau protein).



512 **Fig 4. Population-level variable contributions to prediction of changes in next-day TIL^(Basic) at days**
 513 **directly preceding a change in TIL^(Basic).** The ΔTimeSHAP values on the left panel are from the models
 514 trained on the full variable set whilst the ΔTimeSHAP values on the right panel are from the models trained
 515 without clinician impressions or treatments. ΔTimeSHAP values are interpreted as the relative contributions
 516 of variables towards the difference in model prediction of next-day TIL^(Basic) over the two days directly
 517 preceding the change in TIL^(Basic) (Supplementary Methods S5). Therefore, the study population
 518 represented in this figure is limited to patients who experienced a change in TIL^(Basic) after day two of ICU
 519 stay ($n = 575$). A positive ΔTimeSHAP value signifies association with an increased likelihood of escalation
 520 in next-day TIL^(Basic), whereas a negative ΔTimeSHAP value signifies association with an increased
 521 likelihood of de-escalation. The variables were selected by first identifying the ten variables with non-
 522 missing value tokens with the most negative median ΔTimeSHAP values across the population (above the
 523 ellipses) and then, amongst the remaining variables, selecting the ten with non-missing value tokens with
 524 the most positive median ΔTimeSHAP values (below the ellipses). Each point represents the mean
 525 ΔTimeSHAP value, taken across all 20 repeated cross-validation partitions, for a token preceding an
 526 individual patient's change in TIL^(Basic). The number of points for each variable, therefore, indicates the
 527 relative occurrence of that variable before changes in TIL^(Basic) in the study population. The colour of the
 528 point represents the relative ordered value of a token within a variable, and for unordered variables (e.g.,
 529 patient status during GCS assessment), tokens were sorted alphanumerically (the sort index per possible
 530 unordered variable token is provided in the CENTER-TBI data dictionary: [https://www.center-](https://www.center-tbi.eu/data/dictionary)
 531 [tbi.eu/data/dictionary](https://www.center-tbi.eu/data/dictionary)). Abbreviations: CVDs=cardiovascular diseases, ER=emergency room, F_IO₂=fraction
 532 of inspired oxygen, GCS=Glasgow Coma Scale, ICP=intracranial pressure, P_aO₂=partial pressure of
 533

534 oxygen, TIL=Therapy Intensity Level, TIL^(Basic)=condensed, five-category TIL scale as defined in Table 1,
535 VAP=ventilator-associated pneumonia.

536
537 The most robust predictors of next-day de-escalation in TIL^(Basic) were other clinical
538 indicators of treatment de-escalation (e.g., ending nasogastric feeding), improvement in
539 patients' eye-opening responses, previous administration of barbiturates or propofol, and
540 sufficient control of ICP. Overall, the effects of predictors for TIL^(Basic) escalation were not
541 as robust as those for de-escalation (Fig. 4); however, stratifying the Δ TimeSHAP values
542 by the pre-transition TIL^(Basic) score revealed more consistent associations per level of
543 treatment intensity (Supplementary Fig. S5). For example, high ICP values were robustly
544 predictive of escalations from TIL^(Basic)=2, and the prior administration of certain therapies
545 could be predictive of a future escalation or de-escalation based on the current TIL^(Basic)
546 score (Supplementary Fig. S5). Apart from treatment variables, the factors that
547 contributed the most towards prediction of de-escalation from extreme ICP management
548 (i.e., TIL^(Basic)=4) were neurological improvements in motor and eye response with
549 sufficiently controlled ICP and high blood oxygen saturation (Supplementary Fig. S5). The
550 Δ TimeSHAP values of missing variables (Supplementary Fig. S6) demonstrated that
551 missingness of a variable (e.g., missing report of daily complications) could have a
552 significant de-escalating associative effect on model output.


553

554 ***Conceptual model of changes in treatment intensity***

555

556 We combined the results from the differential explanation of next-day changes in TIL^(Basic)
557 (Fig. 3b–c) and the variable contributions towards prediction of these events (Fig. 4) to
558 produce a conceptual model of day-to-day changes in treatment intensity (Fig. 5). Given
559 the considerable difference in explanation performance between day one and subsequent
560 days of ICU stay, we separated these explanation percentages in our model.

561



562
 563 **Fig 5. Conceptual diagram of factors explaining day-to-day changes in therapeutic intensity.** The
 564 percentage values represent the differential explanation of ordinal variation in next-day changes in TIL^(Basic)
 565 as measured by Somers' D_{xy} . The bolded percentage values represent the 95% confidence interval of
 566 Somers' D_{xy} from days 2–6 of ICU stay, whilst the percentage values below them represent the 95%
 567 confidence interval of Somers' D_{xy} from day 1 of ICU stay (Fig. 3c). The 95% confidence intervals were
 568 derived using bias-corrected bootstrapping (1,000 resamples) to represent the variation across 20 repeated
 569 five-fold cross-validation partitions. The leading static and dynamic pathophysiological factors were
 570 determined by qualitative categorisation of the variables with the highest contribution to next-day changes
 571 in TIL^(Basic) based on Δ TimeSHAP values (Fig. 4). Abbreviations: TIL=Therapy Intensity Level,
 572 TIL^(Basic)=condensed, five-category TIL scale as defined in Table 1.

573

574 Discussion

575

576 We present the first approach to dynamic prediction of future therapy intensity levels (TIL)
 577 in ICP-monitored TBI patients. The TILTomorrow modelling strategy allowed us to exploit
 578 the full clinical context (2,008 variables) captured in a large neurotrauma dataset over
 579 time to uncover factors associated with next-day changes in TIL^(Basic).¹⁹ By including
 580 missing value tokens, models discovered meaningful patterns of missingness
 581 (Supplementary Fig. S6).²⁰ Moreover, our approach mapped clinical events to evolving
 582 predictions at each ordinal level of next-day TIL^(Basic), which is an improvement in
 583 statistical power and clinical information over using a dichotomised measure of
 584 therapeutic intensity (e.g., high-TIL therapies).¹⁵

585

586 The main results of this study are summarised in the conceptual diagram of changes in
 587 TIL^(Basic) (Fig. 5). Amongst all day-to-day steps, the transition from day one to day two had

588 the greatest number of changes in TIL^(Basic) (Fig. 2b), which were also the most predictable
589 (68% [95% CI: 65–72%] explanation, Fig. 3c). From day two onwards, the ordinal
590 explanation of changes in next-day TIL^(Basic) dropped to between 39% (95% CI: 32–47%)
591 and 51% (95% CI: 45–56%). This difference suggests that first-to-second-day changes
592 in treatment intensity might have been the most systematic, possibly associated with
593 primary injury severity and initial patient responses to treatment (Fig. 3c). Later in ICU
594 stay, the predictive influence of a patient's treatment trajectory increased (mostly through
595 informative patterns of de-escalation, Fig. 3b), and that of static factors decreased (Fig.
596 3c). Whilst static factors are poor predictors of TIL^(Basic) on any given day (Fig. 3a and as
597 shown previously¹²), they achieve considerable discrimination performance in prediction
598 of escalations up to day four (AUC: 0.70 [95% CI: 0.65–0.74], Fig. 3b). This may indicate
599 the potential of certain primary injury factors for justifying earlier intervention as to avoid
600 tolerating suboptimal ICP management for a few days. Apart from age, the highest-
601 contributing static factors were space-occupying lesions (also reflected in a recent
602 study²⁸) and bleeding risk factors (Fig. 4), both of which can complicate ICP control. As
603 targets of TIL therapies, ICP and haemodynamic factors are expectedly high-contributing,
604 with different effects based on the pre-transition TIL^(Basic) score (Supplementary Fig. S5).
605 Metabolic complications (i.e., abnormalities in renal or liver function and electrolytic
606 imbalances) have previously been shown to be significantly more common in patients
607 receiving high-TIL therapies¹² and an important marker for physiological endotyping.²⁹
608 Moreover, in a prior study, serial protein biomarkers (in addition to GCS) were key
609 descriptors for clustering TBI patient trajectories in the ICU.³⁰ Therefore, the results from
610 these dynamic variables support the links between TIL and pathophysiology – including
611 systemic factors (e.g., metabolism and inflammation) – after TBI.⁷ This is potentially of
612 clinical importance since protein biomarkers are not measured serially as part of typical
613 routine care outside of research studies (e.g., CENTER-TBI) and a few centres. It is still
614 uncertain whether serial biomarker measurement would improve care outcomes.
615 However, analysing the temporal dynamics of these biomarkers may not only enable a
616 more precise characterisation of patients' treatment needs but also elucidate biological
617 mechanisms underpinning variable treatment response. Finally, whilst we found no
618 significant difference in full-model prediction performance between next-day escalations
619 and de-escalations of TIL^(Basic) (Fig. 3b), high-impact predictors had a more robust signal
620 with de-escalations than they did with escalations (i.e., more consistently negative
621 Δ TimeSHAP values in Fig. 4). This suggests that escalation prediction may be the effect
622 of a complex interaction of factors which is difficult to perceive with Δ TimeSHAP values.

623
624 The underlying assumption of this work is that a more protocolised management of ICP
625 would also be more predictable based on the dynamic condition of a TBI patient. Even
626 with wide inter-centre variation in ICP-targeting treatment,¹⁴ we would expect the
627 measurable factors which rationally drive day-to-day changes in TIL to predict such
628 changes on an individual level. After day two, approximately half of the ordinal variation
629 in day-to-day changes in TIL^(Basic) is unexplained by the full CENTER-TBI variable set,
630 and we propose four reasons for this remaining uncertainty (Fig. 5). First, certain clinical
631 events or complications that could suddenly trigger a (de-)escalation in TIL (e.g.,
632 sustained rise in ICP) might not have been predictable from the day before. Second, there
633 are probably important physiological factors, either unmeasured or not included in our

634 variable set, which would have improved TIL prediction. Most notably, high-resolution
635 waveforms of ICP³¹ and arterial blood pressure (ABP) and their derived metrics (e.g.,
636 pressure-time dose³² and vascular reactivity³³) are more likely to elucidate ICP
637 management decisions than the bihourly clinician-recorded ICP or CPP values available
638 in our variable set.³⁴ Prior analyses of additional physiological modalities – e.g., cerebral
639 microdialysis,³⁵ automated pupillometry,^{36,37} and motion sensing³⁸ – have also
640 demonstrated independent associations with TIL or other short-term endpoints after TBI.
641 Third, assuming different centres have different protocols for ICP management, there may
642 not have been enough patient representation across the spectrum of TBI severity from
643 each centre for TILTomorrow to learn centre-specific guidelines. Fourth, a part of ICP
644 management may be driven by the personal preferences of clinicians in deviation from
645 general guidelines. At the same time, we recognise that predictability does not guarantee
646 a systematised delivery of care. We therefore investigated differential explanation of (Fig.
647 3b–c) and specific variable contributions towards (Fig. 4) changes in TIL to bridge
648 prediction performance to a plausible concept of ICP management (Fig. 5).

649
650 Our results support the use of TIL as an intermediate outcome after TBI.⁷ Specific
651 categories of pathophysiological variables – both static and dynamic – associate well with
652 changes in TIL (Fig. 4 and 5). Since TIL rates the relative risk and complexity of
653 administered treatments, it is logical to minimise TIL when all other factors are held equal.
654 On the other hand, TIL is also a complicated marker of pathophysiology. Since around
655 half of the ordinal variation in changes in TIL is not explained by measured variables (Fig.
656 5), we hypothesise that TIL’s sensitivity to pathophysiology is partially confounded by the
657 personal preferences of clinical teams. Nevertheless, TIL was previously shown to be a
658 stronger indicator of refractory intracranial hypertension than ICP itself and, thus, a more
659 suitable intermediate endpoint for TBI management.⁷ Since the full information pertaining
660 to TIL was only date-stamped in CENTER-TBI, the highest resolution at which we could
661 assess TIL^(Basic) was once per calendar day (Table 1). However, clinicians were also
662 asked to record qualitatively whether treatment intensity was decreasing or increasing
663 every four hours, and these indications (from the day before a change in TIL^(Basic)) were
664 amongst the strongest predictors of next-day changes in TIL^(Basic) (Fig. 4). This result
665 supports a higher resolution TIL for monitoring pathophysiological severity; however, daily
666 TIL scores have been shown to be reliable estimates of hourly TIL scores,⁹ and CENTER-
667 TBI has demonstrated the practical feasibility of daily TIL assessment for a large-scale
668 study ($\leq 2.4\%$ missingness, Fig. 2a).

669
670 TILTomorrow can potentially be useful in other heterogeneous-data-intensive clinical
671 domains as a framework for decoding factors tied to treatment decision-making or other
672 dynamic endpoints. This can inform the design of future causal inference models of
673 individualised treatment effects from observational data.³⁹ TILTomorrow was not
674 conceived for clinical deployment and should not be used for real-time decision support
675 due to concerns of self-fulfilling prophecies, generalisability, and variable robustness.⁴⁰
676 Our focus was on explanatory modelling, to derive insightful patterns from the CENTER-
677 TBI data and quantify the predictability of ICP management. Furthermore, Δ TimeSHAP
678 values on observational data are merely associative and cannot be interpreted for causal
679 inference. We used TimeSHAP in this work to highlight potential areas of investigation

680 from a wider, data-driven approach. Pathophysiological predictors of the need for higher
681 TIL (Fig. 4 and 5) could be useful for improving the timing and precision of future clinical
682 decision-making (e.g., performing decompressive craniectomy in a timely but targeted
683 way) but would require more evidence and feasibility studies than just their predictive
684 power in our data.

685
686 We recognise several additional limitations in this study. TILTomorrow discretised both
687 numerical variables into binned tokens and time into daily windows, which caused some
688 loss of information. Limited by the resolution of available TIL assessments, we chose a
689 daily time window to avoid inconsistent lead times in our prediction task (Fig. 1a). The
690 highest resolution of regularly recorded variables (e.g., ICP) in the CENTER-TBI core
691 study is once every two hours,¹³ and, since TILTomorrow takes the unique set of tokens
692 per daily window prior to embedding, these numerical variables would be reduced to the
693 unique set of quantiles represented in a day (Fig. 1b). An encoding strategy which can
694 integrate high-resolution ICP, CPP, and other clinical information into broader time
695 windows may improve prediction performance. Additionally, the daily TIL^(Basic) score
696 accounts for 33% of the information in the full, 38-point TIL score.⁷ As explained in the
697 Methods, we used TIL^(Basic) as the model endpoint over the full TIL score since it would
698 enable us to uncover factors associated with changes across specific, interpretable bands
699 of treatment intensity (Table 1). Nevertheless, a regression-based prediction of next-day
700 full TIL may capture more nuanced patterns of factors associated with changes in ICP
701 management. Finally, our results may encode recruitment, collection, and clinical biases
702 native to our European patient set. Selective recording of clinical data – with selective
703 missingness – may have biased our analyses, and findings may not generalise to other
704 populations.⁴¹ Given the broad inter-centre variation in ICP-targeted care,¹⁴ the results of
705 TILTomorrow are likely to vary considerably depending on the protocols of specific
706 centres. We encourage investigators to apply the TILTomorrow approach to other
707 longitudinal, granular ICU datasets of TBI patients – particularly in low- and middle-
708 income countries where the burden of TBI is disproportionately higher⁴² – and compare
709 their results.

710

711 **Data and code availability**

712

713 Individual participant data, including data dictionary, the study protocol, and analysis
714 scripts are available online, conditional to approved study proposal, with no end date.
715 Interested investigators must submit a study proposal to the management committee at
716 <https://www.center-tbi.eu/data>. Signed confirmation of a data access agreement is
717 required, and all access must comply with regulatory restrictions imposed on the original
718 study.

719

720 All code used in this project can be found at the following online repository:
721 <https://github.com/sbhattacharyay/TILTomorrow> (DOI: 10.5281/zenodo.11060742).

722

723 **Acknowledgments**

724

725 This research was supported by the National Institute for Health Research (NIHR) Brain
726 Injury MedTech Co-operative. CENTER-TBI was supported by the European Union 7th
727 Framework programme (EC grant 602150). Additional funding was obtained from the
728 Hannelore Kohl Stiftung (Germany), from OneMind (USA), from Integra LifeSciences
729 Corporation (USA), and from NeuroTrauma Sciences (USA). CENTER-TBI also
730 acknowledges interactions and support from the International Initiative for TBI Research
731 (InTBIR) investigators. S.B. is funded by a Gates Cambridge Scholarship. E.B. is funded
732 by the Medical Research Council (MR N013433-1) and by a Gates Cambridge
733 Scholarship. The funders had no role in study design, data collection and analysis,
734 decision to publish, or preparation of the manuscript.

735
736 We are grateful to the patients and families of our study for making our efforts to improve
737 TBI care possible. S.B. would like to thank Kathleen Mitchell-Fox (Princeton University)
738 for offering comments on the manuscript.

739

740 **The CENTER-TBI investigators and participants**

741
742 The co-lead investigators of CENTER-TBI are designated with an asterisk (*), and their
743 contact email addresses are listed below.

744
745 Cecilia Åkerlund¹, Krisztina Amrein², Nada Andelic³, Lasse Andreassen⁴, Audny Anke⁵,
746 Anna Antoni⁶, Gérard Audibert⁷, Philippe Azouvi⁸, Maria Luisa Azzolini⁹, Ronald Bartels¹⁰,
747 Pál Barzó¹¹, Romuald Beauvais¹², Ronny Beer¹³, Bo-Michael Bellander¹⁴, Antonio Belli¹⁵,
748 Habib Benali¹⁶, Maurizio Berardino¹⁷, Luigi Beretta⁹, Morten Blaabjerg¹⁸, Peter Bragge¹⁹,
749 Alexandra Brazinova²⁰, Vibeke Brinck²¹, Joanne Brooker²², Camilla Brorsson²³, Andras
750 Buki²⁴, Monika Bullinger²⁵, Manuel Cabeleira²⁶, Alessio Caccioppola²⁷, Emiliana
751 Calappi²⁷, Maria Rosa Calvi⁹, Peter Cameron²⁸, Guillermo Carbayo Lozano²⁹, Marco
752 Carbonara²⁷, Simona Cavallo¹⁷, Giorgio Chevallard³⁰, Arturo Chierogato³⁰, Giuseppe
753 Citerio^{31,32}, Hans Clusmann³³, Mark Coburn³⁴, Jonathan Coles³⁵, Jamie D. Cooper³⁶,
754 Marta Correia³⁷, Amra Čović³⁸, Nicola Curry³⁹, Endre Czeiter²⁴, Marek Czosnyka²⁶, Claire
755 Dahyot-Fizelier⁴⁰, Paul Dark⁴¹, Helen Dawes⁴², Véronique De Keyser⁴³, Vincent Degos¹⁶,
756 Francesco Della Corte⁴⁴, Hugo den Boogert¹⁰, Bart Depreitere⁴⁵, Đula Đilvesi⁴⁶, Abhishek
757 Dixit⁴⁷, Emma Donoghue²², Jens Dreier⁴⁸, Guy-Loup Dulière⁴⁹, Ari Ercole⁴⁷, Patrick
758 Esser⁴², Erzsébet Ezer⁵⁰, Martin Fabricius⁵¹, Valery L. Feigin⁵², Kelly Foks⁵³, Shirin
759 Frisvold⁵⁴, Alex Furmanov⁵⁵, Pablo Gagliardo⁵⁶, Damien Galanaud¹⁶, Dashiell Gantner²⁸,
760 Guoyi Gao⁵⁷, Pradeep George⁵⁸, Alexandre Ghuysen⁵⁹, Lelde Giga⁶⁰, Ben Glocker⁶¹,
761 Jagoš Golubovic⁴⁶, Pedro A. Gomez⁶², Johannes Gratz⁶³, Benjamin Gravesteijn⁶⁴,
762 Francesca Grossi⁴⁴, Russell L. Gruen⁶⁵, Deepak Gupta⁶⁶, Juanita A. Haagsma⁶⁴, Iain
763 Haitsma⁶⁷, Raimund Helbok¹³, Eirik Helseth⁶⁸, Lindsay Horton⁶⁹, Jilske Huijben⁶⁴, Peter
764 J. Hutchinson⁷⁰, Bram Jacobs⁷¹, Stefan Jankowski⁷², Mike Jarrett²¹, Ji-yao Jiang⁵⁸, Faye
765 Johnson⁷³, Kelly Jones⁵², Mladen Karan⁴⁶, Angelos G. Koliass⁷⁰, Erwin Kompanje⁷⁴, Daniel
766 Kondziella⁵¹, Evgenios Kornaropoulos⁴⁷, Lars-Owe Koskinen⁷⁵, Noémi Kovács⁷⁶, Ana
767 Kowark⁷⁷, Alfonso Lagares⁶², Linda Lanyon⁵⁸, Steven Laureys⁷⁸, Fiona Lecky^{79,80}, Didier
768 Ledoux⁷⁸, Rolf Lefering⁸¹, Valerie Legrand⁸², Aurelie Lejeune⁸³, Leon Levi⁸⁴, Roger
769 Lightfoot⁸⁵, Hester Lingsma⁶⁴, Andrew I.R. Maas^{43,86,*}, Ana M. Castaño-León⁶², Marc
770 Maegele⁸⁷, Marek Majdan²⁰, Alex Manara⁸⁸, Geoffrey Manley⁸⁹, Costanza Martino⁹⁰,

771 Hugues Maréchal⁴⁹, Julia Mattern⁹¹, Catherine McMahon⁹², Béla Melegh⁹³, David
772 Menon^{47,*}, Tomas Menovsky^{43,86}, Ana Mikolic⁶⁴, Benoit Misset⁷⁸, Visakh
773 Muraleedharan⁵⁸, Lynnette Murray²⁸, Ancuta Negru⁹⁴, David Nelson¹, Virginia
774 Newcombe⁴⁷, Daan Nieboer⁶⁴, József Nyirádi², Otesile Olubukola⁷⁹, Matej Oresic⁹⁵,
775 Fabrizio Ortolano²⁷, Aarno Palotie^{96,97,98}, Paul M. Parizel⁹⁹, Jean-François Payen¹⁰⁰,
776 Natascha Perera¹², Vincent Perlberg¹⁶, Paolo Persona¹⁰¹, Wilco Peul¹⁰², Anna Piippo-
777 Karjalainen¹⁰³, Matti Pirinen⁹⁶, Dana Pisica⁶⁴, Horia Ples⁹⁴, Suzanne Polinder⁶⁴, Inigo
778 Pomposo²⁹, Jussi P. Posti¹⁰⁴, Louis Puybasset¹⁰⁵, Andreea Radoi¹⁰⁶, Arminas
779 Ragauskas¹⁰⁷, Rahul Raj¹⁰³, Malinka Rambadagalla¹⁰⁸, Isabel Retel Helmrich⁶⁴, Jonathan
780 Rhodes¹⁰⁹, Sylvia Richardson¹¹⁰, Sophie Richter⁴⁷, Samuli Ripatti⁹⁶, Saulius Rocka¹⁰⁷,
781 Cecilie Roe¹¹¹, Olav Roise^{112,113}, Jonathan Rosand¹¹⁴, Jeffrey V. Rosenfeld¹¹⁵, Christina
782 Rosenlund¹¹⁶, Guy Rosenthal⁵⁵, Rolf Rossaint⁷⁷, Sandra Rossi¹⁰¹, Daniel Rueckert⁶¹
783 Martin Rusnák¹¹⁷, Juan Sahuquillo¹⁰⁶, Oliver Sakowitz^{91,118}, Renan Sanchez-Porras¹¹⁸,
784 Janos Sandor¹¹⁹, Nadine Schäfer⁸¹, Silke Schmidt¹²⁰, Herbert Schoechl¹²¹, Guus
785 Schoonman¹²², Rico Frederik Schou¹²³, Elisabeth Schwendenwein⁶, Charlie Sewalt⁶⁴,
786 Ranjit D. Singh¹⁰², Toril Skandsen^{124,125}, Peter Smielewski²⁶, Abayomi Sorinola¹²⁶,
787 Emmanuel Stamatakis⁴⁷, Simon Stanworth³⁹, Robert Stevens¹²⁷, William Stewart¹²⁸,
788 Ewout W. Steyerberg^{64,129}, Nino Stocchetti¹³⁰, Nina Sundström¹³¹, Riikka Takala¹³²,
789 Viktória Tamás¹²⁶, Tomas Tamosuitis¹³³, Mark Steven Taylor²⁰, Aurore Thibaut⁷⁸, Braden
790 Te Ao⁵², Olli Tenovuo¹⁰⁴, Alice Theadom⁵², Matt Thomas⁸⁸, Dick Tibboel¹³⁴, Marjolein
791 Timmers⁷⁴, Christos Tolia¹³⁵, Tony Trapani²⁸, Cristina Maria Tudora⁹⁴, Andreas
792 Unterberg⁹¹, Peter Vajkoczy¹³⁶, Shirley Vallance²⁸, Egils Valeinis⁶⁰, Zoltán Vámos⁵⁰,
793 Mathieu van der Jagt¹³⁷, Gregory Van der Steen⁴³, Joukje van der Naalt⁷¹, Jeroen T.J.M.
794 van Dijck¹⁰², Inge A. M. van Erp¹⁰², Thomas A. van Essen¹⁰², Wim Van Hecke¹³⁸, Caroline
795 van Heugten¹³⁹, Ernest van Veen⁶⁴, Thijs Vande Vyvere¹⁴⁰, Roel P. J. van Wijk¹⁰², Alessia
796 Vargiolu³², Emmanuel Vega⁸³, Kimberley Velt⁶⁴, Jan Verheyden¹³⁸, Paul M. Vespa¹⁴¹,
797 Anne Vik^{124,142}, Rimantas Vilcinis¹³³, Victor Volovici⁶⁷, Nicole von Steinbüchel³⁸, Daphne
798 Voormolen⁶⁴, Petar Vulekovic⁴⁶, Kevin K.W. Wang¹⁴³, Daniel Whitehouse⁴⁷, Eveline
799 Wieggers⁶⁴, Guy Williams⁴⁷, Lindsay Wilson⁶⁹, Stefan Winzeck⁴⁷, Stefan Wolf¹⁴⁴, Zhihui
800 Yang¹¹⁴, Peter Ylén¹⁴⁵, Alexander Younsi⁹¹, Frederick A. Zeiler^{47,146}, Veronika
801 Zelinkova²⁰, Agate Ziverte⁶⁰, Tommaso Zoerle²⁷

802
803 ¹Department of Physiology and Pharmacology, Section of Perioperative Medicine and
804 Intensive Care, Karolinska Institutet, Stockholm, Sweden

805 ²János Szentágothai Research Centre, University of Pécs, Pécs, Hungary

806 ³Division of Clinical Neuroscience, Department of Physical Medicine and Rehabilitation,
807 Oslo University Hospital and University of Oslo, Oslo, Norway

808 ⁴Department of Neurosurgery, University Hospital Northern Norway, Tromsø, Norway

809 ⁵Department of Physical Medicine and Rehabilitation, University Hospital Northern
810 Norway, Tromsø, Norway

811 ⁶Trauma Surgery, Medical University Vienna, Vienna, Austria

812 ⁷Department of Anesthesiology & Intensive Care, University Hospital Nancy, Nancy,
813 France

814 ⁸Raymond Poincaré hospital, Assistance Publique – Hôpitaux de Paris, Paris, France

815 ⁹Department of Anesthesiology & Intensive Care, S Raffaele University Hospital, Milan,
816 Italy

- 817 ¹⁰Department of Neurosurgery, Radboud University Medical Center, Nijmegen, The
818 Netherlands
- 819 ¹¹Department of Neurosurgery, University of Szeged, Szeged, Hungary
- 820 ¹²International Projects Management, ARTTIC, Munchen, Germany
- 821 ¹³Department of Neurology, Neurological Intensive Care Unit, Medical University of
822 Innsbruck, Innsbruck, Austria
- 823 ¹⁴Department of Neurosurgery & Anesthesia & intensive care medicine, Karolinska
824 University Hospital, Stockholm, Sweden
- 825 ¹⁵NIHR Surgical Reconstruction and Microbiology Research Centre, Birmingham, UK
- 826 ¹⁶Anesthésie-Réanimation, Assistance Publique – Hôpitaux de Paris, Paris, France
- 827 ¹⁷Department of Anesthesia & ICU, AOU Città della Salute e della Scienza di Torino -
828 Orthopedic and Trauma Center, Torino, Italy
- 829 ¹⁸Department of Neurology, Odense University Hospital, Odense, Denmark
- 830 ¹⁹BehaviourWorks Australia, Monash Sustainability Institute, Monash University, Victoria,
831 Australia
- 832 ²⁰Department of Public Health, Faculty of Health Sciences and Social Work, Trnava
833 University, Trnava, Slovakia
- 834 ²¹Quesgen Systems Inc., Burlingame, California, USA
- 835 ²²Australian & New Zealand Intensive Care Research Centre, Department of
836 Epidemiology and Preventive Medicine, School of Public Health and Preventive
837 Medicine, Monash University, Melbourne, Australia
- 838 ²³Department of Surgery and Perioperative Science, Umeå University, Umeå, Sweden
- 839 ²⁴Department of Neurosurgery, Medical School, University of Pécs, Hungary and
840 Neurotrauma Research Group, János Szentágothai Research Centre, University of
841 Pécs, Hungary
- 842 ²⁵Department of Medical Psychology, Universitätsklinikum Hamburg-Eppendorf,
843 Hamburg, Germany
- 844 ²⁶Brain Physics Lab, Division of Neurosurgery, Dept of Clinical Neurosciences, University
845 of Cambridge, Addenbrooke's Hospital, Cambridge, UK
- 846 ²⁷Neuro ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, Milan, Italy
- 847 ²⁸ANZIC Research Centre, Monash University, Department of Epidemiology and
848 Preventive Medicine, Melbourne, Victoria, Australia
- 849 ²⁹Department of Neurosurgery, Hospital of Cruces, Bilbao, Spain
- 850 ³⁰NeuroIntensive Care, Niguarda Hospital, Milan, Italy
- 851 ³¹School of Medicine and Surgery, Università Milano Bicocca, Milano, Italy
- 852 ³²NeuroIntensive Care Unit, Department Neuroscience, IRCCS Fondazione San Gerardo
853 dei Tintori, Monza, Italy
- 854 ³³Department of Neurosurgery, Medical Faculty RWTH Aachen University, Aachen,
855 Germany
- 856 ³⁴Department of Anesthesiology and Intensive Care Medicine, University Hospital Bonn,
857 Bonn, Germany
- 858 ³⁵Department of Anesthesia & Neurointensive Care, Cambridge University Hospital NHS
859 Foundation Trust, Cambridge, UK
- 860 ³⁶School of Public Health & PM, Monash University and The Alfred Hospital, Melbourne,
861 Victoria, Australia
- 862 ³⁷Radiology/MRI department, MRC Cognition and Brain Sciences Unit, Cambridge, UK

- 863 ³⁸Institute of Medical Psychology and Medical Sociology, Universitätsmedizin Göttingen,
864 Göttingen, Germany
- 865 ³⁹Oxford University Hospitals NHS Trust, Oxford, UK
- 866 ⁴⁰Intensive Care Unit, CHU Poitiers, Poitiers, France
- 867 ⁴¹University of Manchester NIHR Biomedical Research Centre, Critical Care Directorate,
868 Salford Royal Hospital NHS Foundation Trust, Salford, UK
- 869 ⁴²Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes
870 University, Oxford, UK
- 871 ⁴³Department of Neurosurgery, Antwerp University Hospital, Edegem, Belgium
- 872 ⁴⁴Department of Anesthesia & Intensive Care, Maggiore Della Carità Hospital, Novara,
873 Italy
- 874 ⁴⁵Department of Neurosurgery, University Hospitals Leuven, Leuven, Belgium
- 875 ⁴⁶Department of Neurosurgery, Clinical centre of Vojvodina, Faculty of Medicine,
876 University of Novi Sad, Novi Sad, Serbia
- 877 ⁴⁷Division of Anaesthesia, University of Cambridge, Addenbrooke's Hospital, Cambridge,
878 UK
- 879 ⁴⁸Center for Stroke Research Berlin, Charité – Universitätsmedizin Berlin, corporate
880 member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute
881 of Health, Berlin, Germany
- 882 ⁴⁹Intensive Care Unit, CHR Citadelle, Liège, Belgium
- 883 ⁵⁰Department of Anaesthesiology and Intensive Therapy, University of Pécs, Pécs,
884 Hungary
- 885 ⁵¹Departments of Neurology, Clinical Neurophysiology and Neuroanesthesiology, Region
886 Hovedstaden Rigshospitalet, Copenhagen, Denmark
- 887 ⁵²National Institute for Stroke and Applied Neurosciences, Faculty of Health and
888 Environmental Studies, Auckland University of Technology, Auckland, New Zealand
- 889 ⁵³Department of Neurology, Erasmus MC, Rotterdam, the Netherlands
- 890 ⁵⁴Department of Anesthesiology and Intensive care, University Hospital Northern Norway,
891 Tromsø, Norway
- 892 ⁵⁵Department of Neurosurgery, Hadassah-hebrew University Medical center, Jerusalem,
893 Israel
- 894 ⁵⁶Fundación Instituto Valenciano de Neurorehabilitación (FIVAN), Valencia, Spain
- 895 ⁵⁷Department of Neurosurgery, Shanghai Renji hospital, Shanghai Jiaotong
896 University/school of medicine, Shanghai, China
- 897 ⁵⁸Karolinska Institutet, INCF International Neuroinformatics Coordinating Facility,
898 Stockholm, Sweden
- 899 ⁵⁹Emergency Department, CHU, Liège, Belgium
- 900 ⁶⁰Neurosurgery clinic, Pauls Stradins Clinical University Hospital, Riga, Latvia
- 901 ⁶¹Department of Computing, Imperial College London, London, UK
- 902 ⁶²Department of Neurosurgery, Hospital Universitario 12 de Octubre, Madrid, Spain
- 903 ⁶³Department of Anesthesia, Critical Care and Pain Medicine, Medical University of
904 Vienna, Austria
- 905 ⁶⁴Department of Public Health, Erasmus Medical Center-University Medical Center,
906 Rotterdam, The Netherlands
- 907 ⁶⁵College of Health and Medicine, Australian National University, Canberra, Australia

- 908 ⁶⁶Department of Neurosurgery, Neurosciences Centre & JPN Apex trauma centre, All
909 India Institute of Medical Sciences, New Delhi-110029, India
- 910 ⁶⁷Department of Neurosurgery, Erasmus MC, Rotterdam, the Netherlands
- 911 ⁶⁸Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
- 912 ⁶⁹Division of Psychology, University of Stirling, Stirling, UK
- 913 ⁷⁰Division of Neurosurgery, Department of Clinical Neurosciences, Addenbrooke's
914 Hospital & University of Cambridge, Cambridge, UK
- 915 ⁷¹Department of Neurology, University of Groningen, University Medical Center
916 Groningen, Groningen, Netherlands
- 917 ⁷²Neurointensive Care, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield,
918 UK
- 919 ⁷³Salford Royal Hospital NHS Foundation Trust Acute Research Delivery Team, Salford,
920 UK
- 921 ⁷⁴Department of Intensive Care and Department of Ethics and Philosophy of Medicine,
922 Erasmus Medical Center, Rotterdam, The Netherlands
- 923 ⁷⁵Department of Clinical Neuroscience, Neurosurgery, Umeå University, Umeå, Sweden
- 924 ⁷⁶Hungarian Brain Research Program - Grant No. KTIA_13_NAP-A-II/8, University of
925 Pécs, Pécs, Hungary
- 926 ⁷⁷Department of Anaesthesiology, University Hospital of Aachen, Aachen, Germany
- 927 ⁷⁸Cyclotron Research Center, University of Liège, Liège, Belgium
- 928 ⁷⁹Centre for Urgent and Emergency Care Research (CURE), Health Services Research
929 Section, School of Health and Related Research (SchARR), University of Sheffield,
930 Sheffield, UK
- 931 ⁸⁰Emergency Department, Salford Royal Hospital, Salford UK
- 932 ⁸¹Institute of Research in Operative Medicine (IFOM), Witten/Herdecke University,
933 Cologne, Germany
- 934 ⁸²VP Global Project Management CNS, ICON, Paris, France
- 935 ⁸³Department of Anesthesiology-Intensive Care, Lille University Hospital, Lille, France
- 936 ⁸⁴Department of Neurosurgery, Rambam Medical Center, Haifa, Israel
- 937 ⁸⁵Department of Anesthesiology & Intensive Care, University Hospitals Southampton
938 NHS Trust, Southampton, UK
- 939 ⁸⁶Department of Translational Neuroscience, Faculty of Medicine and Health Science,
940 University of Antwerp, Antwerp, Belgium
- 941 ⁸⁷Cologne-Merheim Medical Center (CMMC), Department of Traumatology, Orthopedic
942 Surgery and Sportmedicine, Witten/Herdecke University, Cologne, Germany
- 943 ⁸⁸Intensive Care Unit, Southmead Hospital, Bristol, Bristol, UK
- 944 ⁸⁹Department of Neurological Surgery, University of California, San Francisco, California,
945 USA
- 946 ⁹⁰Department of Anesthesia & Intensive Care, M. Bufalini Hospital, Cesena, Italy
- 947 ⁹¹Department of Neurosurgery, University Hospital Heidelberg, Heidelberg, Germany
- 948 ⁹²Department of Neurosurgery, The Walton centre NHS Foundation Trust, Liverpool, UK
- 949 ⁹³Department of Medical Genetics, University of Pécs, Pécs, Hungary
- 950 ⁹⁴Department of Neurosurgery, Emergency County Hospital Timisoara, Timisoara,
951 Romania
- 952 ⁹⁵School of Medical Sciences, Örebro University, Örebro, Sweden
- 953 ⁹⁶Institute for Molecular Medicine Finland, University of Helsinki, Helsinki, Finland

- 954 ⁹⁷Analytic and Translational Genetics Unit, Department of Medicine; Psychiatric &
955 Neurodevelopmental Genetics Unit, Department of Psychiatry; Department of
956 Neurology, Massachusetts General Hospital, Boston, MA, USA
- 957 ⁹⁸Program in Medical and Population Genetics; The Stanley Center for Psychiatric
958 Research, The Broad Institute of MIT and Harvard, Cambridge, MA, USA
- 959 ⁹⁹Department of Radiology, University of Antwerp, Edegem, Belgium
- 960 ¹⁰⁰Department of Anesthesiology & Intensive Care, University Hospital of Grenoble,
961 Grenoble, France
- 962 ¹⁰¹Department of Anesthesia & Intensive Care, Azienda Ospedaliera Università di
963 Padova, Padova, Italy
- 964 ¹⁰²Dept. of Neurosurgery, Leiden University Medical Center, Leiden, The Netherlands and
965 Dept. of Neurosurgery, Medical Center Haaglanden, The Hague, The Netherlands
- 966 ¹⁰³Department of Neurosurgery, Helsinki University Central Hospital
- 967 ¹⁰⁴Division of Clinical Neurosciences, Department of Neurosurgery and Turku Brain Injury
968 Centre, Turku University Hospital and University of Turku, Turku, Finland
- 969 ¹⁰⁵Department of Anesthesiology and Critical Care, Pitié -Salpêtrière Teaching Hospital,
970 Assistance Publique, Hôpitaux de Paris and University Pierre et Marie Curie, Paris,
971 France
- 972 ¹⁰⁶Neurotraumatology and Neurosurgery Research Unit (UNINN), Vall d'Hebron
973 Research Institute, Barcelona, Spain
- 974 ¹⁰⁷Department of Neurosurgery, Kaunas University of technology and Vilnius University,
975 Vilnius, Lithuania
- 976 ¹⁰⁸Department of Neurosurgery, Rezekne Hospital, Latvia
- 977 ¹⁰⁹Department of Anaesthesia, Critical Care & Pain Medicine NHS Lothian & University
978 of Edinburgh, Edinburgh, UK
- 979 ¹¹⁰Director, MRC Biostatistics Unit, Cambridge Institute of Public Health, Cambridge, UK
- 980 ¹¹¹Department of Physical Medicine and Rehabilitation, Oslo University
981 Hospital/University of Oslo, Oslo, Norway
- 982 ¹¹²Division of Orthopedics, Oslo University Hospital, Oslo, Norway
- 983 ¹¹³Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway
- 984 ¹¹⁴Broad Institute, Cambridge MA Harvard Medical School, Boston MA, Massachusetts
985 General Hospital, Boston MA, USA
- 986 ¹¹⁵National Trauma Research Institute, The Alfred Hospital, Monash University,
987 Melbourne, Victoria, Australia
- 988 ¹¹⁶Department of Neurosurgery, Odense University Hospital, Odense, Denmark
- 989 ¹¹⁷International Neurotrauma Research Organisation, Vienna, Austria
- 990 ¹¹⁸Klinik für Neurochirurgie, Klinikum Ludwigsburg, Ludwigsburg, Germany
- 991 ¹¹⁹Division of Biostatistics and Epidemiology, Department of Preventive Medicine,
992 University of Debrecen, Debrecen, Hungary
- 993 ¹²⁰Department Health and Prevention, University Greifswald, Greifswald, Germany
- 994 ¹²¹Department of Anaesthesiology and Intensive Care, AUVA Trauma Hospital, Salzburg,
995 Austria
- 996 ¹²²Department of Neurology, Elisabeth-TweeSteden Ziekenhuis, Tilburg, the Netherlands
- 997 ¹²³Department of Neuroanesthesia and Neurointensive Care, Odense University Hospital,
998 Odense, Denmark

- 999 ¹²⁴Department of Neuromedicine and Movement Science, Norwegian University of
1000 Science and Technology, NTNU, Trondheim, Norway
- 1001 ¹²⁵Department of Physical Medicine and Rehabilitation, St.Olavs Hospital, Trondheim
1002 University Hospital, Trondheim, Norway
- 1003 ¹²⁶Department of Neurosurgery, University of Pécs, Pécs, Hungary
- 1004 ¹²⁷Division of Neuroscience Critical Care, John Hopkins University School of Medicine,
1005 Baltimore, USA
- 1006 ¹²⁸Department of Neuropathology, Queen Elizabeth University Hospital and University of
1007 Glasgow, Glasgow, UK
- 1008 ¹²⁹Dept. of Department of Biomedical Data Sciences, Leiden University Medical Center,
1009 Leiden, The Netherlands
- 1010 ¹³⁰Department of Pathophysiology and Transplantation, Milan University, and
1011 Neuroscience ICU, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico,
1012 Milano, Italy
- 1013 ¹³¹Department of Radiation Sciences, Biomedical Engineering, Umeå University, Umeå,
1014 Sweden
- 1015 ¹³²Perioperative Services, Intensive Care Medicine and Pain Management, Turku
1016 University Hospital and University of Turku, Turku, Finland
- 1017 ¹³³Department of Neurosurgery, Kaunas University of Health Sciences, Kaunas, Lithuania
- 1018 ¹³⁴Intensive Care and Department of Pediatric Surgery, Erasmus Medical Center, Sophia
1019 Children’s Hospital, Rotterdam, The Netherlands
- 1020 ¹³⁵Department of Neurosurgery, Kings college London, London, UK
- 1021 ¹³⁶Neurologie, Neurochirurgie und Psychiatrie, Charité – Universitätsmedizin Berlin,
1022 Berlin, Germany
- 1023 ¹³⁷Department of Intensive Care Adults, Erasmus MC– University Medical Center
1024 Rotterdam, Rotterdam, the Netherlands
- 1025 ¹³⁸icoMetrix NV, Leuven, Belgium
- 1026 ¹³⁹Movement Science Group, Faculty of Health and Life Sciences, Oxford Brookes
1027 University, Oxford, UK
- 1028 ¹⁴⁰Radiology Department, Antwerp University Hospital, Edegem, Belgium
- 1029 ¹⁴¹Director of Neurocritical Care, University of California, Los Angeles, USA
- 1030 ¹⁴²Department of Neurosurgery, St.Olavs Hospital, Trondheim University Hospital,
1031 Trondheim, Norway
- 1032 ¹⁴³Department of Emergency Medicine, University of Florida, Gainesville, Florida, USA
- 1033 ¹⁴⁴Department of Neurosurgery, Charité – Universitätsmedizin Berlin, corporate member
1034 of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of
1035 Health, Berlin, Germany
- 1036 ¹⁴⁵VTT Technical Research Centre, Tampere, Finland
- 1037 ¹⁴⁶Section of Neurosurgery, Department of Surgery, Rady Faculty of Health Sciences,
1038 University of Manitoba, Winnipeg, MB, Canada
- 1039
- 1040 *Co-lead investigators: andrew.maas@uza.be (AIRM) and dkm13@cam.ac.uk (DM)
- 1041

1042 **References**

1043

- 1044 1 Meyfroidt G, Bouzat P, Casaer MP, *et al.* Management of moderate to severe
1045 traumatic brain injury: an update for the intensivist. *Intensive Care Med* 2022; **48**:
1046 649–66.
- 1047 2 Maas AIR, Menon DK, Adelson PD, *et al.* Traumatic brain injury: integrated
1048 approaches to improve prevention, clinical care, and research. *Lancet Neurol* 2017;
1049 **16**: 987–1048.
- 1050 3 Maas AIR, Menon DK, Manley GT, *et al.* Traumatic brain injury: progress and
1051 challenges in prevention, clinical care, and research. *Lancet Neurol* 2022; **21**: 1004–
1052 60.
- 1053 4 Hawryluk GWJ, Aguilera S, Buki A, *et al.* A management algorithm for patients with
1054 intracranial pressure monitoring: the Seattle International Severe Traumatic Brain
1055 Injury Consensus Conference (SIBICC). *Intensive Care Med* 2019; **45**: 1783–94.
- 1056 5 Carney N, Totten AM, O’Reilly C, *et al.* Guidelines for the Management of Severe
1057 Traumatic Brain Injury, Fourth Edition. *Neurosurgery* 2017; **80**: 6.
- 1058 6 Stocchetti N, Maas AIR. Traumatic Intracranial Hypertension. *N Engl J Med* 2014;
1059 **370**: 2121–30.
- 1060 7 Bhattacharyay S, Beqiri E, Zuercher P, *et al.* Therapy Intensity Level Scale for
1061 Traumatic Brain Injury: Clinimetric Assessment on Neuro-Monitored Patients Across
1062 52 European Intensive Care Units. *J Neurotrauma* 2024; **41**: 887–909.
- 1063 8 Maas AIR, Harrison-Felix CL, Menon D, *et al.* Standardizing Data Collection in
1064 Traumatic Brain Injury. *J Neurotrauma* 2011; **28**: 177–87.
- 1065 9 Zuercher P, Groen JL, Aries MJH, *et al.* Reliability and Validity of the Therapy
1066 Intensity Level Scale: Analysis of Clinimetric Properties of a Novel Approach to
1067 Assess Management of Intracranial Pressure in Traumatic Brain Injury. *J*
1068 *Neurotrauma* 2016; **33**: 1768–74.
- 1069 10 Maas AIR, Menon DK, Steyerberg EW, *et al.* Collaborative European NeuroTrauma
1070 Effectiveness Research in Traumatic Brain Injury (CENTER-TBI): A Prospective
1071 Longitudinal Observational Study. *Neurosurgery* 2015; **76**: 67–80.
- 1072 11 Steyerberg EW, Wiegers E, Sewalt C, *et al.* Case-mix, care pathways, and
1073 outcomes in patients with traumatic brain injury in CENTER-TBI: a European
1074 prospective, multicentre, longitudinal, cohort study. *Lancet Neurol* 2019; **18**: 923–34.
- 1075 12 Huijben JA, Dixit A, Stocchetti N, *et al.* Use and impact of high intensity treatments
1076 in patients with traumatic brain injury across Europe: a CENTER-TBI analysis. *Crit*
1077 *Care* 2021; **25**: 78.

- 1078 13 Bhattacharyay S, Caruso PF, Åkerlund C, *et al.* Mining the contribution of intensive
1079 care clinical course to outcome after traumatic brain injury. *Npj Digit Med* 2023; **6**: 1–
1080 11.
- 1081 14 Huijben JA, Wiegers EJA, Lingsma HF, *et al.* Changing care pathways and
1082 between-center practice variations in intensive care for traumatic brain injury across
1083 Europe: a CENTER-TBI analysis. *Intensive Care Med* 2020; **46**: 995–1004.
- 1084 15 Bhattacharyay S, Milosevic I, Wilson L, *et al.* The leap to ordinal: Detailed functional
1085 prognosis after traumatic brain injury with a flexible modelling approach. *PLOS ONE*
1086 2022; **17**: e0270973.
- 1087 16 Doiron D, Marcon Y, Fortier I, Burton P, Ferretti V. Software Application Profile: Opal
1088 and Mica: open-source software solutions for epidemiological data management,
1089 harmonization and dissemination. *Int J Epidemiol* 2017; **46**: 1372–8.
- 1090 17 Monteiro M, Newcombe VFJ, Mathieu F, *et al.* Multiclass semantic segmentation
1091 and quantification of traumatic brain injury lesions on head CT using deep learning:
1092 an algorithm development and multicentre validation study. *Lancet Digit Health* 2020;
1093 **2**: e314–22.
- 1094 18 Jain S, Vyvere TV, Terzopoulos V, *et al.* Automatic Quantification of Computed
1095 Tomography Features in Acute Traumatic Brain Injury. *J Neurotrauma* 2019; **36**:
1096 1794–803.
- 1097 19 Deasy J, Liò P, Ercole A. Dynamic survival prediction in intensive care units from
1098 heterogeneous time series without the need for variable selection or curation. *Sci*
1099 *Rep* 2020; **10**: 22129.
- 1100 20 Ercole A, Dixit A, Nelson DW, *et al.* Imputation strategies for missing baseline
1101 neurological assessment covariates after traumatic brain injury: A CENTER-TBI
1102 study. *PLOS ONE* 2021; **16**: e0253425.
- 1103 21 Tsamardinos I, Greasidou E, Borboudakis G. Bootstrapping the out-of-sample
1104 predictions for efficient and accurate cross-validation. *Mach Learn* 2018; **107**: 1895–
1105 922.
- 1106 22 Van Calster B, Nieboer D, Vergouwe Y, De Cock B, Pencina MJ, Steyerberg EW. A
1107 calibration hierarchy for risk models was defined: from utopia to empirical data. *J Clin*
1108 *Epidemiol* 2016; **74**: 167–76.
- 1109 23 Somers RH. A New Asymmetric Measure of Association for Ordinal Variables. *Am*
1110 *Sociol Rev* 1962; **27**: 799–811.
- 1111 24 Van Calster B, Van Belle V, Vergouwe Y, Steyerberg EW. Discrimination ability of
1112 prediction models for ordinal outcomes: Relationships between existing measures
1113 and a new measure. *Biom J* 2012; **54**: 674–85.

- 1114 25 Bento J, Saleiro P, Cruz AF, Figueiredo MAT, Bizarro P. TimeSHAP: Explaining
1115 Recurrent Models through Sequence Perturbations. In: Proceedings of the 27th ACM
1116 SIGKDD Conference on Knowledge Discovery & Data Mining. New York, NY, USA:
1117 Association for Computing Machinery, 2021: 2565–73.
- 1118 26 Lundberg SM, Lee S-I. A Unified Approach to Interpreting Model Predictions. In:
1119 Guyon I, Luxburg UV, Bengio S, *et al.*, eds. Advances in Neural Information
1120 Processing Systems 30. NIPS, 2017: 4765–74.
- 1121 27 Shapley LS. A Value for n-Person Games. In: Contributions to the Theory of Games
1122 II. Princeton University Press, 1953: 307–18.
- 1123 28 Brossard C, Grèze J, de Busschère J-A, *et al.* Prediction of therapeutic intensity
1124 level from automatic multiclass segmentation of traumatic brain injury lesions on CT-
1125 scans. *Sci Rep* 2023; **13**: 20155.
- 1126 29 Åkerlund CAI, Holst A, Stocchetti N, *et al.* Clustering identifies endotypes of
1127 traumatic brain injury in an intensive care cohort: a CENTER-TBI study. *Crit Care*
1128 2022; **26**: 228.
- 1129 30 Åkerlund CAI, Holst A, Bhattacharyay S, *et al.* Clinical descriptors of disease
1130 trajectories in patients with traumatic brain injury in the intensive care unit (CENTER-
1131 TBI): a multicentre observational cohort study. *Lancet Neurol* 2024; **23**: 71–80.
- 1132 31 Czosnyka M, Pickard JD. Monitoring and interpretation of intracranial pressure. *J*
1133 *Neurol Neurosurg Psychiatry* 2004; **75**: 813–21.
- 1134 32 Åkerlund CAI, Donnelly J, Zeiler FA, *et al.* Impact of duration and magnitude of
1135 raised intracranial pressure on outcome after severe traumatic brain injury: A
1136 CENTER-TBI high-resolution group study. *PLOS ONE* 2020; **15**: e0243427.
- 1137 33 Beqiri E, Ercole A, Aries MJH, *et al.* Towards autoregulation-oriented management
1138 after traumatic brain injury: increasing the reliability and stability of the CPPopt
1139 algorithm. *J Clin Monit Comput* 2023; **37**: 963–76.
- 1140 34 Zoerle T, Birg T, Carbonara M, *et al.* Accuracy of Manual Intracranial Pressure
1141 Recording Compared to a Computerized High-Resolution System: A CENTER-TBI
1142 Analysis. *Neurocrit Care* 2023; **38**: 781–90.
- 1143 35 Eiden M, Christinat N, Chakrabarti A, *et al.* Discovery and validation of temporal
1144 patterns involved in human brain ketometabolism in cerebral microdialysis fluids of
1145 traumatic brain injury patients. *eBioMedicine* 2019; **44**: 607–17.
- 1146 36 Banco P, Taccone FS, Sourd D, *et al.* Prediction of neurocritical care intensity
1147 through automated infrared pupillometry and transcranial doppler in blunt traumatic
1148 brain injury: the NOPE study. *Eur J Trauma Emerg Surg* 2024; published online Jan
1149 16. DOI:10.1007/s00068-023-02435-1.

- 1150 37 Luz Teixeira T, Peluso L, Banco P, *et al.* Early Pupillometry Assessment in
1151 Traumatic Brain Injury Patients: A Retrospective Study. *Brain Sci* 2021; **11**: 1657.
- 1152 38 Bhattacharyay S, Rattray J, Wang M, *et al.* Decoding accelerometry for classification
1153 and prediction of critically ill patients with severe brain injury. *Sci Rep* 2021; **11**:
1154 23654.
- 1155 39 Bica I, Alaa AM, Lambert C, van der Schaar M. From Real-World Patient Data to
1156 Individualized Treatment Effects Using Machine Learning: Current and Future
1157 Methods to Address Underlying Challenges. *Clin Pharmacol Ther* 2020; **109**: 87–100.
- 1158 40 Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An
1159 overview of clinical decision support systems: benefits, risks, and strategies for
1160 success. *Npj Digit Med* 2020; **3**: 1–10.
- 1161 41 Futoma J, Simons M, Panch T, Doshi-Velez F, Celi LA. The myth of generalisability
1162 in clinical research and machine learning in health care. *Lancet Digit Health* 2020; **2**:
1163 e489–92.
- 1164 42 Clark D, Joannides A, Adeleye AO, *et al.* Casemix, management, and mortality of
1165 patients receiving emergency neurosurgery for traumatic brain injury in the Global
1166 Neurotrauma Outcomes Study: a prospective observational cohort study. *Lancet*
1167 *Neurol* 2022; **21**: 438–49.
- 1168